Aufricht C, Balzar E, Steger H, Lothaller M A, Frenzel K, Kohlhauser C, Kiss H, Khoss A E, Kernova T
Department of Pediatrics, University of Vienna, Austria.
Acta Paediatr. 1993 Nov;82(11):959-62. doi: 10.1111/j.1651-2227.1993.tb12608.x.
Subcutaneous recombinant human erythropoietin (rHuEpo) treatment of renal anemia was performed in four boys and eight girls on CAPD, aged 0.8-12.5 (mean 7.4) years. In contrast to previous studies, our therapeutic goal was not set with a hematocrit of 30% but with full correction of anemia. Following a maximum weekly rHuEpo dosage of median 120 (range 100-240) IU/kg body weight, hematocrit increased in 10 children from 24 (14-29)% within 12 (4-17) weeks to 40.1 (33.5-48.4)%. The weekly increase in hematocrit was 1.27 (0.5-3.1)%. The corrected reticulocyte count increased from 1.3 (0.7-1.8)% to 2.3 (1.4-3.9)% within 4 (2-6) weeks. Eight children fulfilled the protocol; six with an uncomplicated course were able to maintain a hematocrit of 37.1 (35.1-42.7)% with only one sc medication per week of approximately two-thirds of their highest weekly rHuEpo dosage. No serious adverse effect of rHuEpo therapy was observed.
对4名男孩和8名女孩进行了皮下注射重组人促红细胞生成素（rHuEpo）治疗肾性贫血，这些患儿接受持续性非卧床腹膜透析（CAPD）治疗，年龄在0.8至12.5岁（平均7.4岁）之间。与以往研究不同，我们的治疗目标不是将血细胞比容设定为30%，而是完全纠正贫血。在最大每周rHuEpo剂量中位数为120（范围100 - 240）IU/kg体重的情况下，10名儿童的血细胞比容在12（4 - 17）周内从24（14 - 29）%升至40.1（33.5 - 48.4）%。血细胞比容每周增加1.27（0.5 - 3.1）%。校正网织红细胞计数在4（2 - 6）周内从1.3（0.7 - 1.8）%增至2.3（1.4 - 3.9）%。8名儿童完成了方案；6名病程无并发症的儿童能够通过每周皮下注射一次约为其最高每周rHuEpo剂量三分之二的药物，将血细胞比容维持在37.1（35.1 - 42.7）%。未观察到rHuEpo治疗的严重不良反应。
